Success Metrics

Active Trials

2(50%)

Phase Distribution

Ph phase_1

25%

Ph not_applicable

25%

Ph phase_3

25%

Ph early_phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

1(25.0%)

Phase 3Large-scale testing

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Other(1)

Detailed Status

Active, not recruiting1

Enrolling by invitation1

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (25.0%)

Phase 11 (25.0%)

Phase 31 (25.0%)

N/A1 (25.0%)

Trials by Status

active_not_recruiting125%

enrolling_by_invitation125%

recruiting125%

unknown125%

Recent Activity

2 active trials

Showing 4 of 4

enrolling_by_invitationnot_applicable

Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

NCT05714904

Clinical Trials (4)

Showing 4 of 4 trials

NCT07307469Not Applicable

Compassionate Administration of ZVS101e Injection for Extended Treatment

Enrolling By Invitation

NCT06743646Phase 3

Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Recruiting

NCT05832684Phase 1

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Active Not Recruiting

NCT05714904Early Phase 1

Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Unknown

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4